
ProQR Therapeutics N.V. Net Income | PRQR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income ProQR Therapeutics N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.2 M | -27.8 M | -27.7 M | -64.2 M | -61.7 M | -46.6 M | -56.5 M | -36.9 M | -43.6 M | -39.1 M | -20.8 M | -12.1 M | -3.25 M | - | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.25 M | -64.2 M | -37.1 M |
Quarterly Net Income ProQR Therapeutics N.V.
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.2 M | -11 M | -12.2 M | -10.1 M | -27.8 M | -8.11 M | -2.69 M | -7.66 M | -27.7 M | -5.42 M | -7.98 M | -8.86 M | - | -23.3 M | -13.5 M | -14.4 M | -18.2 M | -15.1 M | -15.8 M | -12.6 M | -13.2 M | -13.2 M | -4.12 M | -16.1 M | -18.6 M | -12.2 M | -11.7 M | -14.2 M | - | -5.99 M | -7.4 M | - | - | - | -11.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.69 M | -42.2 M | -13.8 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Supernus Pharmaceuticals
SUPN
|
-38.6 M | $ 36.28 | 1.88 % | $ 2.05 B | ||
|
TG Therapeutics
TGTX
|
447 M | $ 66.13 | 5.45 % | $ 9.54 B | ||
|
Aphria Inc.
APHA
|
-84.6 M | - | -0.45 % | $ 4.87 B | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
-4.32 M | - | -0.90 % | $ 104 M | ||
|
Chiasma, Inc.
CHMA
|
-74.8 M | - | -6.00 % | $ 238 M | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
-57.4 M | - | - | $ 376 M | ||
|
Cellect Biotechnology Ltd.
APOP
|
16.8 M | - | 0.38 % | $ 12.9 M | ||
|
AzurRx BioPharma, Inc.
AZRX
|
-32.7 T | - | 2.07 % | $ 34.4 M | ||
|
Cerecor Inc.
CERC
|
-63.5 M | - | -1.68 % | $ 283 M | ||
|
Constellation Pharmaceuticals, Inc.
CNST
|
-126 M | - | - | $ 1.63 B | ||
|
Auris Medical Holding Ltd.
EARS
|
-8.2 M | - | -1.77 % | $ 39.2 M | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
-113 M | - | 0.34 % | $ 2.98 B | ||
|
ERYTECH Pharma S.A.
ERYP
|
-228 K | - | 1.3 % | $ 27.7 M | ||
|
GW Pharmaceuticals plc
GWPH
|
-58.1 M | - | - | $ 6.81 B | ||
|
Kadmon Holdings, Inc.
KDMN
|
-109 M | - | - | $ 1.7 B | ||
|
Liminal BioSciences
LMNL
|
622 K | - | - | $ 256 M | ||
|
argenx SE
ARGX
|
1.29 B | $ 940.88 | -0.7 % | $ 57.7 B | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-124 M | $ 2.86 | -4.25 % | $ 24.3 M | ||
|
Neos Therapeutics, Inc.
NEOS
|
-16.9 M | - | -2.54 % | $ 57.2 M | ||
|
Xenetic Biosciences
XBIO
|
-2.68 M | $ 1.52 | -5.59 % | $ 2.59 M | ||
|
Odonate Therapeutics, Inc.
ODT
|
-126 M | - | -3.18 % | $ 58.5 M | ||
|
Orphazyme A/S
ORPH
|
-633 M | - | -2.25 % | $ 31.3 M | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
-79.6 M | - | -10.74 % | $ 89.9 M | ||
|
Pandion Therapeutics, Inc.
PAND
|
-38.1 M | - | - | $ 1.77 B | ||
|
Xenon Pharmaceuticals
XENE
|
-346 M | $ 37.93 | -2.19 % | $ 3.01 B | ||
|
Xeris Pharmaceuticals
XERS
|
554 K | $ 16.95 | 0.92 % | $ 2.72 B | ||
|
22nd Century Group
XXII
|
-5.05 M | $ 0.38 | -14.05 % | $ 69.9 K | ||
|
Translate Bio, Inc.
TBIO
|
-53.8 M | - | - | $ 2.81 B | ||
|
Trillium Therapeutics Inc.
TRIL
|
-59.3 M | - | - | $ 1.94 B | ||
|
Urovant Sciences Ltd.
UROV
|
-147 M | - | - | $ 532 M | ||
|
Acceleron Pharma Inc.
XLRN
|
-125 M | - | - | $ 10.9 B | ||
|
Zealand Pharma A/S
ZEAL
|
-1.02 B | - | 0.52 % | $ 821 M | ||
|
Zogenix, Inc.
ZGNX
|
-209 M | - | -4.97 % | $ 664 M | ||
|
Yunhong International
ZGYH
|
-797 K | - | 0.10 % | $ 92.2 M | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
-80 M | - | -7.58 % | $ 264 M | ||
|
Taysha Gene Therapies
TSHA
|
-109 M | $ 3.99 | -0.25 % | $ 1.28 B | ||
|
Zentalis Pharmaceuticals
ZNTL
|
-137 M | $ 1.38 | -7.38 % | $ 99.2 M | ||
|
Zoetis
ZTS
|
2.67 B | $ 85.52 | 2.44 % | $ 37.9 B | ||
|
Vanda Pharmaceuticals
VNDA
|
-220 M | $ 3.76 | -1.44 % | $ 222 M | ||
|
Vericel Corporation
VCEL
|
16.5 M | $ 58.63 | 1.29 % | $ 2.95 B | ||
|
Veracyte
VCYT
|
66.4 M | $ 25.54 | 5.41 % | $ 2.01 B | ||
|
VistaGen Therapeutics
VTGN
|
-69.7 M | $ 0.2 | 5.69 % | $ 7.61 M | ||
|
Viking Therapeutics
VKTX
|
-360 M | $ 26.19 | -2.59 % | $ 2.95 B | ||
|
Voyager Therapeutics
VYGR
|
-120 M | $ 1.68 | 10.2 % | $ 98.6 M | ||
|
Zai Lab Limited
ZLAB
|
-176 M | $ 22.11 | -6.03 % | $ 24.2 B | ||
|
Verrica Pharmaceuticals
VRCA
|
-17.9 M | $ 2.9 | -7.64 % | $ 30.9 M | ||
|
Wave Life Sciences Ltd.
WVE
|
-204 M | $ 2.77 | -2.64 % | $ 467 M | ||
|
Zymeworks
ZYME
|
-212 M | $ 26.04 | 0.77 % | $ 1.34 B | ||
|
XBiotech
XBIT
|
-45.5 M | $ 1.76 | -1.12 % | $ 53.7 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
-1.03 M | $ 1.54 | -4.94 % | $ 1.04 B |